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With an objective to develop Complementary and Alternative Medicine for the treatment of diabetic
nephropathy, the present study investigated the protective effects of methanolic extract of Punica
granatum leaves (MPGL) in streptozotocin-induced diabetic nephropathy. Diabetic nephropathy has
become a leading cause of end stage renal failure worldwide. P. granatum, due to its anti-diabetic, anti-
inﬂammatory and antioxidant activities may retard the progression of diabetic nephropathy. In this
study, diabetes was induced by a single injection of streptozotocin (STZ, 45 mg/kg, i.p.) in rats. STZ-
diabetic rats were treated with oral doses of MPGL (100, 200 and 400 mg/kg) for 8 weeks. At the end
of the experimental period, body and kidney weight and blood glucose levels were determined. Serum
and urine parameters were investigated. Antioxidant enzymes and lipid peroxide levels were determined
in the kidney along with histopathological examination of the same. MPGL signiﬁcantly increased body
weight, lowered blood glucose levels and ameliorated kidney hypertrophy index in the STZ-diabetic rats.
The extract also decreased the levels of creatinine, blood urea nitrogen, total cholesterol, triglycerides,
advanced glycation end products and albumin in serum and urine, respectively. MPGL signiﬁcantly
increased the antioxidant parameters in the kidney. Histological evaluation revealed that MPGL treated
STZ-diabetic rats demonstrated reduced vacuolar degeneration of tubules; periodic acid Schiff base (PAS)
positivity staining intensity in glomeruli and basement membrane thickening. Present ﬁndings provide
experimental evidence that MPGL has potential antioxidant, antihyperglycemic and anti-glycation ac-
tivities which might be helpful in slowing the progression of diabetic nephropathy.
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by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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ditional and Complementary1. Introduction
Diabetes mellitus is characterized by hyperglycemia resulting
from defects in insulin secretion, insulin action, or both. Sustained
hyperglycemia is further associated with long term damage,
dysfunction and failure of various organs and is amajor factor in the
development of many complications in patients with diabetes.1,2
Moreover, diabetes is the most common cause of progressive kid-
ney failure leading to dialysis or transplantation.3 Nephropathy is
reported to develop in 30e40% of patients with diabetes and has
become a leading cause of end stage renal failure worldwide.4,5
Diabetic nephropathy is characterized by structural as well as
functional abnormalities.6 Poor glycemic control and accumulation
of advanced glycation end products (AGEs) play a signiﬁcant role in
the development of diabetic nephropathy. Furthermore, advanced
glycation end products have been implicated in tissue damage
associated with diabetic nephropathy. The clinical and pathologicalrsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
etic nephropathy in streptozotocin-induced diabetic rats by Punica
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tion7 along with accumulation of extracellular matrix,3 thickening
of basement membranes, mesangial expansion, hypertrophy and
glomerular epithelial cell (podocyte) loss within the glomeruli.6
Patients with diabetic nephropathy have a progressive decline in
glomerular function.8 Antihypertensive agents, particularly those
targeting the renin angiotensin system, such as angiotensin con-
verting enzyme inhibitors, angiotensin receptor-1 antagonists are
reported to be the most effective treatments for progressive dia-
betic nephropathy, to date. However, these treatments are not
capable of preventing the onset of diabetic nephropathy.6
Medicinal plants play a signiﬁcant role in the development of
potent therapeutic agents. Herbal medicines have been used to
treat various human diseases. Moreover, the demand for herbal
medicines is increasing day by day. Punica granatum, generally
called as Pomegranate, is a deciduous tree belonging to the family
Punicaceae. In Ayurveda, P. granatum is considered as “a pharmacy
unto itself” and is used as an antiparasitic, antiviral, antifungal,
antibacterial, hemostatic, anticarcinogenic agent and as a blood
tonic. The most therapeutically beneﬁcial pomegranate constitu-
ents are found to be ellagic acid, ellagitannins (punicalagins,
punicalin, punicafolin), punicic acid, ﬂavonoids, anthocyanidins,
anthocyanins, ﬂavonols, ﬂavone glycosides and ﬂavones.9 In addi-
tion to this, P. granatum is one of the natural products having a
potential hypoglycemic activity in which constituents like ole-
anolic, ursolic and gallic acids have been associated with antidia-
betic effects.10
The leaves of P. granatum are known for their anti-inﬂammatory,
anti-cholinesterase and cytotoxic activities.11 Previous studies have
reported the presence of high amounts of ellagic acid, an efﬁcient
free radical scavenger, in P. granatum leaf extract thus, demon-
strating a potent antioxidant activity.12 P. granatum leaves extract
has been found to be highly effective in managing diabetic com-
plications such as hyperlipidemia and thus, prevent the defects in
lipid metabolism.13 Further, the ethanolic extract of pomegranate
leaves has shown a promising role as an anti-obesity agent in the
high fat diet induced obesity model.14 Taking all this into consid-
eration, the objective of the present study was to assess the pro-
tective effects of methanolic extract of P. granatum leaves (MPGL) in
streptozotocin (STZ)-induced diabetic nephropathy.
2. Material and methods
2.1. Procurement and authentication of plant
P. granatum leaves were collected from Nashik, Maharashtra;
India in the month of January, 2014 and identiﬁed by Dr. Ganesh
Iyer, Botany Department, Ruia College, Mumbai (Maharashtra). A
voucher specimen (No. 2014/01) was deposited at the Department
of Pharmacology, Institute of Chemical Technology, Mumbai
(Maharashtra, India).
2.2. Preparation of plant extract
The leaves were washed with distilled water, shade dried and
made into a coarse powder. The powder was initially defatted using
petroleum ether followed by extraction with methanol using
Soxhlet apparatus. The extract obtained was concentrated under
reduced pressure using rotary evaporator (yield 50.707%) and
stored in an airtight container for subsequent use.
2.3. Preliminary phytochemical screening
The phytochemical investigation of MPGL was carried out
following the standard procedure of Wagner et al. (1996).15 PlantPlease cite this article in press as: Mestry SN, et al., Attenuation of diab
granatum Linn. leaves extract, Journal of Traditional and Complementaryextract was screened for the presence of steroids, triterpenoids,
glycosides, ﬂavonoids, saponins and tannins. The total phenolic
content was quantiﬁed by calibration curve obtained by measuring
the absorbance of the known concentrations of gallic acid standard
solutions [10e100 mg/ml in methanol]. The results were calculated
and expressed in mg of gallic acid equivalent (GAE) per gram of
extract. The total ﬂavonoid content was measured by the
aluminium chloride colorimetric method and expressed as mg of
rutin equivalents per gram of extract.16
2.4. Experimental
2.4.1. Animals
Healthy male Sprague Dawley rats weighing between 250
and300 g were procured from National Institute of Biosciences,
Pune (Maharashtra) and maintained in polypropylene cages at
ambient temperature of 22 ± 1 C and relative humidity of 50e60%
with a 12 h light/dark cycle in registered animal house (87/1999/
CPCSEA) at Institute of Chemical Technology, Matunga, Mumbai.
The animal experiments were carried out as per the guidelines of
the Committee for the Purpose of Control and Supervision of Ex-
periments on Animals (CPCSEA), India and approved by the Insti-
tutional Animal Ethics Committee (IAEC), Institute of Chemical
Technology, Mumbai, (Approval No. ICT/IAEC/2014/P38).
Throughout the experimental period, the animals were fed with
standard pellet diet (Amrut Brand, Sangali, India) and water ad
libitum.
2.4.2. Experimental design
Diabetes was induced by a single injection of streptozotocin
(STZ, 45 mg/kg, i.p. freshly prepared in 0.1 M citrate buffer pH 4.5)
in rats.17 The control group received equal volume of vehicle (0.1 M
citrate buffer, pH 4.5). Blood glucose level was measured from tail
vein using glucose meter (ACCU-CHEK advantage), seven days after
induction. Rats with blood glucose level above 14 mmol/L were
considered as diabetic and were used for further study by initiating
the treatment. MPGL was administered daily to rats per oral for 8
weeks. The animals were divided into 5 groups: Normal control
group (n ¼ 6), STZ-induced diabetic group (n ¼ 6), STZ-induced
diabetic group treated with MPGL 100 mg/kg (n ¼ 6), STZ-
induced diabetic group treated with MPGL 200 mg/kg (n ¼ 6)
and STZ-induced diabetic group treated with MPGL 400 mg/kg
(n ¼ 6). The three doses of extract were selected on the basis of the
acute oral toxicity study reported on the plant in addition to the
previous studies carried out on the plant.13,18 Blood glucose levels
were measured before treatment and on 1st, 2nd, 4th, 6th & 8th
weeks respectively. Body weight of each animal was determined at
the initiation and end of the study. On the completion of 8 weeks,
blood was withdrawn via retro orbital plexus. Blood samples were
centrifuged at 1300g for separation of serum and stored at 20 C
until assay. At the end of the experimental period, animals were
perfused with saline to remove the traces of blood cells from the
organs.
2.5. Preparation of kidney homogenate
Immediately after sacriﬁce, both the kidneys were dissected;
rinsed with isotonic saline and weighed. After weighing, each
kidney was cut into two halves. One half was used for histo-
pathological evaluation. Other half was minced and a homogenate
was prepared with 10% (w/v) phosphate-buffered (0.1 M, pH 7.4)
using a homogenizer. The kidney homogenate was centrifuged
and the supernatant was estimated for kidney antioxidant
parameters.etic nephropathy in streptozotocin-induced diabetic rats by Punica
Medicine (2016), http://dx.doi.org/10.1016/j.jtcme.2016.06.008
Fig. 1. TLC analysis of methanolic extract of Punica granatum leaves (MPGL). (A)
Visualization of MPGL and Luteolin standard at 254 nm (Rf value: 0.37). (B) Visuali-
zation of MPGL and Luteolin standard at 366 nm (Rf value: 0.37). (C) Visualization of
MPGL and b-sitosterol standard at 366 nm (Rf value: 0.46).
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Serumwas used for the estimation of albumin, creatinine, blood
urea nitrogen (BUN), cholesterol and triglyceride levels. Pooled 24 h
urine was evaluated for creatinine and albumin value. The esti-
mation of the above mentioned parameters was carried out using
biochemical kits (ACCUREX, Biomedical Pvt. Ltd). For the determi-
nation of ﬂuorescent AGE, a 96-plate spectrophotoﬂuorimeter was
employed. 100 ml of serum sample was placed in each well. Fluo-
rescence intensity was read at 440 nm after excitation at 370 nm.
Results were expressed as relative ﬂuorescence intensity.
2.7. Kidney antioxidant parameters
5-5-dithiobis (2-nitrobenzoic acid) (DTNB) reagent was used to
estimate reduced glutathione (GSH) level in tissue homogenates
and the absorbance was read at 412 nm. The amount of GSH in the
sample was calculated in microgram per ml from a standard curve
obtained and represented in GSH per total tissue protein. Evalua-
tion of kidney homogenate for lipid peroxidation levels, superoxide
dismutase (SOD) and catalase (CAT) activities was carried out
following the method published by Nishi et al., and Halliwell and
Chirico.19,20
2.8. Kidney histopathological examination
Kidney tissues were immediately preserved in 10% neutral
buffered formalin, dehydrated through graded alcohol series,
embedded in parafﬁn, cut into 5 mm sections and stained with
hematoxylin and eosin (H&E) and periodic acid Schiff base (PAS)
method. The slides were examined by light microscopy under 400
magniﬁcation for microscopic alterations of pathological
signiﬁcance.
3. Results
3.1. Preliminary phytochemical screening
The preliminary phytochemical screening carried out on MPGL
revealed the presence of phytoconstituents such as steroids, gly-
cosides, saponins, ﬂavonoids, tannins and carbohydrates (Fig. 1).
The total phenolic content was found to be 328.75 ± 0.625 mg of
gallic acid/g of extract whereas the total ﬂavonoid content was
found to be 126.667 ± 6.5 mg of rutin/g of extract respectively.
3.2. Body weight
During 8-week experiment, STZ-diabetic rats exhibited signiﬁ-
cant weight loss when compared with normal rats. At the end of 8
weeks treatment, the body weight of rats treated with MPGL at the
dose of 200 mg/kg and 400 mg/kg was signiﬁcantly increased
compared with the diabetic control group (Table 1).
3.3. Kidney weight and kidney hypertrophy
The kidney weight and kidney hypertrophy index in STZ-
diabetic rats were signiﬁcantly increased as compared to those in
the normal control group. Treatment of STZ-diabetic rats with
MPGL at the dose of 200 mg/kg and 400 mg/kg ameliorated kidney
hypertrophy index (Table 1).
3.4. Blood glucose level
Administration of STZ led to signiﬁcant increase in fasting blood
glucose levels in the diabetic group as compared to the normalPlease cite this article in press as: Mestry SN, et al., Attenuation of diab
granatum Linn. leaves extract, Journal of Traditional and Complementarycontrol group throughout 8 weeks after induction. Furthermore,
STZ-diabetic rats treated with 100 mg/kg MPGL demonstrated
decrease in the fasting blood glucose levels at the end of 8 weeks
whereas STZ-diabetic rats treated with 200 mg/kg and 400 mg/kg
MPGL showed a signiﬁcant decrease in the fasting blood glucose
levels at the end of 6 weeks (Table 2).3.5. Serum and urine parameters
The STZ-diabetic rats showed a signiﬁcant decrease in the level
of creatinine in urine with a signiﬁcant increase in serum as
compared to the normal control group. After treatment with MPGL,
the creatinine content increased signiﬁcantly in urine with a sig-
niﬁcant decrease in serum. The STZ-diabetic rats showed a signif-
icant increase in the albumin content in urine, with a signiﬁcant
decrease in the level of albumin in serum as compared to the
normal group. The albumin level of the STZ-diabetic rats treated
with MPGL was brought back to normal. The STZ-diabetic rats
exhibited signiﬁcant increase in the blood urea nitrogen content
whereas treatment with MPGL signiﬁcantly decreased this level. In
STZ-diabetic rats a signiﬁcant increase in the level of serum tri-
glycerides and cholesterol was observed as compared to the normal
control group. However, STZ-diabetic rats treated with MPGL
demonstrated a signiﬁcant decrease in the level of triglycerides and
cholesterol. Advanced glycation end products were signiﬁcantlyetic nephropathy in streptozotocin-induced diabetic rats by Punica
Medicine (2016), http://dx.doi.org/10.1016/j.jtcme.2016.06.008
Table 1
Effect of Punica granatum leaves extract on body weight and kidney weight of STZ-diabetic rats.
Groups Body weight (gm)
8th week
Mean ± S.E.M.
Kidney weight (gm)
Mean ± S.E.M.
Kidney hypertrophy (kidney weight/Body weight) %
Control 400.17 ± 9.82 1.2 ± 0.05 0.30 ± 0.01
Diabetic 217.83 ± 15.63### 1.43 ± 0.10# 0.60 ± 0.03###
100 mg/kg MPGL 231.33 ± 11.66 1.24 ± 0.05 0.54 ± 0.03
200 mg/kg MPGL 263.17 ± 9.02* 1.18 ± 0.05* 0.44 ± 0.02***
400 mg/kg MPGL 311.67 ± 10.72*** 1.12 ± 0.06** 0.36 ± 0.02***
* Treatment group was compared with diabetic control, p < 0.05; ** Treatment group was compared with diabetic control, p < 0.01; *** Treatment group was compared with
diabetic control, p < 0.001; ### Diabetic group was compared with normal control, p < 0.001, using one-way ANOVA with Dunnett's test.
Table 2
Effect of Punica granatum leaves extract on blood glucose level of STZ-diabetic rats.
Blood glucose level (mmol/L)
(Mean ± S.E.M.)
Groups After Induction 1st week 2nd week 4th week 6th week 8th week
Control 4.25 ± 0.33 4.26 ± 0.26 4.11 ± 0.33 4.34 ± 0.33 4.18 ± 0.33 4.29 ± 0.33
Diabetic 24.83 ± 3.04### 25.42 ± 3.22### 26.48 ± 1.47### 23.96 ± 1.93### 27.03 ± 2.61### 26.78 ± 1.55###
100 mg/kg MPGL 24.85 ± 4.00 24.41 ± 1.39 25.45 ± 1.66 23.33 ± 2.49 24.13 ± 1.88 20.14 ± 0.97*
200 mg/kg MPGL 25.86 ± 2.64 23.49 ± 3.79 17.89 ± 3.49* 23.43 ± 3.46 18.5 ± 2.11* 18.57 ± 2.11*
400 mg/kg MPGL 24.5 ± 2.51 20.85 ± 4.13 15.93 ± 1.11** 18.03 ± 1.76 17.81 ± 2.70* 16.86 ± 2.81**
* Treatment group was compared with diabetic control, p < 0.05; ** Treatment group was compared with diabetic control, p < 0.01; *** Treatment group was compared with
diabetic control, p < 0.001; ### Diabetic group was compared with normal control, p < 0.001, using one-way ANOVA with Dunnett's test.
Table 4
Effect of Punica granatum leaves extract on urine parameters of STZ-diabetic rats.
Groups Urine albumin
gm/24 h
Urine creatinine
mg/24 h
(Mean ± S.E.M.)
Control 0.09 ± 0.01 22.90 ± 0.41
Diabetic 0.40 ± 0.03### 12.53 ± 0.23###
100 mg/kg MPGL 0.22 ± 0.06** 14.31 ± 0.86
200 mg/kg MPGL 0.22 ± 0.03** 16.59 ± 0.05***
400 mg/kg MPGL 0.16 ± 0.02*** 21.73 ± 0.55***
* Treatment groupwas comparedwith diabetic control, p < 0.05; ** Treatment group
was compared with diabetic control, p < 0.01; *** Treatment group was compared
with diabetic control, p < 0.001; ### Diabetic group was compared with normal
control, p < 0.001, using one-way ANOVA with Dunnett's test.
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rats. Administration of MPGL to STZ-diabetic rats reduced the
advanced glycation end products signiﬁcantly when compared to
the negative control group (Tables 3 and 4).
3.6. Kidney antioxidant parameters
Signiﬁcantly higher levels of Malondialdehyde (MDA) (a marker
of lipid peroxidation) were detected in the kidney of STZ-diabetic
rats. SOD, CAT and GSH activities were signiﬁcantly decreased in
the kidney of STZ-diabetic rats as compared to the normal control
rats. Treatment with MPGL signiﬁcantly decreased the increased
level of MDA at the dose of 200 and 400 mg/kg and signiﬁcantly
increased the decreased activities of SOD and GSH at all dose levels.
Signiﬁcant elevation of catalase activity was observed at the dose of
400 mg/kg of MPGL (Fig. 2).
3.7. Histopathological evaluation
Control rats did not show any abnormal morphological changes
in H&E and PAS stained kidney specimens. Normal architecture and
glomerular size and basement membrane thickness were observed
in case of control group. According to H&E stained kidney speci-
mens of STZ-diabetic rats, moderate to severe vacuolarTable 3
Effect of Punica granatum leaves extract on serum parameters of STZ-diabetic rats.
Groups Serum albumin
gm %
Serum creatinine mg/dl BUN
mg/dl
(Mean ± S
Control 6.37 ± 0.02 1 ± 0.12 15.89 ± 2.8
Diabetic 2.46 ± 0.15### 1.47 ± 0.03## 32.62 ± 2.1
100 mg/kg MPGL 2.20 ± 0.42 1.15 ± 0.17 23.00 ± 0.2
200 mg/kg MPGL 3.66 ± 0.60 0.95 ± 0.05** 21.62 ± 0.9
400 mg/kg MPGL 4.55 ± 0.36** 0.80 ± 0.00*** 17.73 ± 1.2
* Treatment group was compared with diabetic control, p < 0.05; ** Treatment group wa
diabetic control, p < 0.001; ### Diabetic group was compared with normal control, p <
Please cite this article in press as: Mestry SN, et al., Attenuation of diab
granatum Linn. leaves extract, Journal of Traditional and Complementarydegeneration of tubules and increased glomerular space was
observed. MPGL signiﬁcantly reduced vacuolar degeneration of
tubules at 200 mg/kg and 400 mg/kg dose levels but failed to
demonstrate the same at 100 mg/kg (Fig. 3). Kidneys stained with
PAS exhibited moderate intensity PAS positivity in glomeruli and
mild degree basement membrane thickening in the negative con-
trol group. Treatment with MPGL reduced the PAS positivity
staining intensity in glomeruli at all dose levels and basement
membrane thickening in STZ-diabetic rats at 400 mg/kg dose level
respectively (Fig. 4).Total
Cholesterol
mg %
Triglycerides
mg %
Serum AGE
RFU
.E.M.)
4 56.31 ± 3.15 77.87 ± 11.42 14726.88 ± 646.37
2### 77.31 ± 8.12# 151.38 ± 3.89### 25619.980 ± 622.98###
7** 63.85 ± 3.84 129.45 ± 8.65 25092.75 ± 297.75
9*** 53.63 ± 3.55** 81.83 ± 9.24*** 21275.3 ± 356.7***
1*** 51.16 ± 3.18** 78.94 ± 2.92*** 20028.33 ± 419.83***
s compared with diabetic control, p < 0.01; *** Treatment group was compared with
0.001, using one-way ANOVA with Dunnett's test.
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Fig. 2. Effect of Punica granatum leaves extract on antioxidant parameters in STZ-diabetic rats. (A) GSH in kidney homogenate of control, STZ-diabetic rats and MPGL treated rats. (B)
SOD in kidney homogenate of control, STZ-diabetic rats and MPGL treated rats. (C) Catalase in kidney homogenate of control, STZ-diabetic rats and MPGL treated rats. (D) Lipid
peroxidation in kidney homogenate of control, STZ-diabetic rats and MPGL treated rats. * Treatment group was compared with diabetic control, p < 0.05; ** Treatment group was
compared with diabetic control, p < 0.01; *** Treatment group was compared with diabetic control, p < 0.001; ### Diabetic group was compared with normal control, p < 0.001,
using one-way ANOVA with Dunnett's test.
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Diabetes is a complex endocrine disorder involving insulin
deﬁciency which leads to chronic hyperglycemia with disturbances
of carbohydrate, fat and protein metabolism. It is estimated that
more than 300 million people worldwide will have diabetes mel-
litus by 2025.21 Diabetic nephropathy, a serious complication of
diabetes mellitus, is the most common cause of end stage renal
failure. About 15e25% of type 1 diabetes patients and 30e40% of
patients with type 2 diabetes suffer from diabetic nephropathy.22 In
spite of the availability of therapeutic agents which retard the
progression of diabetic nephropathy, there has been renewed in-
terest in the use of herbal medicines in order to prevent the genesis
of this complication.
P. granatum L., a deciduous shrub, the leaves of which are rich in
polyphenolic compounds including tannins and ﬂavonoids23 has
aroused great interest due to its antidiabetic potential which could be
consideredasa leadto furtherstudytheeffectof thispartof theplanton
diabetic complications such as nephropathy.24 Taking this into consid-
eration, in our present investigation, we have evaluated the protective
effects of MPGL on STZ-induced diabetic nephropathy in rats.
Streptozotocin has been an agent of choice to induce experi-
mental diabetes mellitus due to its ability to induce speciﬁc ne-
crosis of the pancreatic beta cells resulting in degranulation and
loss of capacity to secrete insulin.25,26 Thus, in the present study,Please cite this article in press as: Mestry SN, et al., Attenuation of diab
granatum Linn. leaves extract, Journal of Traditional and ComplementarySTZwas used for induction of diabetes in rats. Administration of STZ
led to signiﬁcant increase in blood glucose level which was lowered
on treatment with MPGL thus conﬁrming the antihyperglycemic
activity of the extract as reported by earlier established studies.13,24
However, up to 4 weeks no signiﬁcant difference was observed in
the glucose level of MPGL treated groups as compared to diabetic
group. One of the possible reasons for this may be that the extract
does not possess a strong anti-diabetic activity. The concentration
of active principles at the given doses might not be capable in
controlling hyperglycemia in the initial weeks. The active principles
in the extract might take time to reach sufﬁcient concentration at
the target site. It could also be due to principles such as reducing
sugars or other carbohydrates whichmight interfere with the onset
of hypoglycemic effect of MPGL. Several reports have stated the
diminished hypoglycemic responses of extract due to the presence
of reducing sugars which could give rise to free glucose after
digestion that may tend to rise blood glucose levels in the face of
the hypoglycemic actions by the active hypoglycemic agents.27
STZ-induced diabetes is associated with signiﬁcant reduction in
the body weight due to hyperglycemia, hypoinsulinemia,25
increased muscle wasting and loss of tissue proteins.28 The body
weight of STZ-diabetic rats was progressively reduced and treat-
ment with MPGL improved the body weight signiﬁcantly, thus
indicating prevention of muscle tissue damage caused due to
hyperglycemia.etic nephropathy in streptozotocin-induced diabetic rats by Punica
Medicine (2016), http://dx.doi.org/10.1016/j.jtcme.2016.06.008
Fig. 3. Photomicrographs of kidney (Hematoxylin and Eosin staining under a light microscope at 400 magniﬁcation). A: Control rats; B: STZ-diabetic rats; C: 100 mg/kg MPGL
treated group; D: 200 mg/kg MPGL treated group; E: 400 mg/kg MPGL treated group. G: glomeruli, T: tubules, GS: glomerular space, VD: vacuolar degeneration.
S.N. Mestry et al. / Journal of Traditional and Complementary Medicine xxx (2016) 1e86Increase in the weight of kidney (hypertrophy) in proportion to
the body weight is observed in STZ-induced rats. Local alterations in
the production of one or more growth factors such as over expres-
sion of transforming growth factor e beta 1 in the kidney especially
in proximal convoluted tubules cells and glomerular mesangial cells
are proposed in the development of renal hypertrophy. An increase
in the rate of protein synthesis and/or decrease in the degradation of
renal extracellular components might also lead to renal hypertro-
phy.25 MPGL treatment reduced kidney/body weight ratio, thus
demonstrating reversal of kidney hypertrophy in STZ-diabetic rats.
Diabetes mellitus leads to fatty liver, hypercholesterolemia and
hypertriglyceridemia.24 Moreover, elevated cholesterol levels are
associated with diabetic nephropathy.29 These increased levels
were reversed towards normal after treatment with MPGL, thus
demonstrating its potential to improve lipid metabolism. Hypo-
albuminaemia is considered as a strongest predictor of death in
patients with renal failure. Albumin is by far the most abundant
protein in nephrotic urine.30 In STZ-diabetic rats, serum albuminPlease cite this article in press as: Mestry SN, et al., Attenuation of diab
granatum Linn. leaves extract, Journal of Traditional and Complementaryconcentration was decreased signiﬁcantly with an increase in the
albumin levels in urine, thus demonstrating that albuminuria was
related to deteriorating kidney function. Treatment with MPGL
normalized these levels thus, exhibiting its beneﬁcial role against
microalbuminuria. Increased serum creatinine level and BUN along
with decreased excretion of creatinine in the urine are indicators of
the development of diabetic nephropathy.22 Reversal of these ef-
fects was observed in STZ-diabetic rats treated with MPGL. The
formation of AGEs in renal tissue plays a crucial role in the devel-
opment of diabetic nephropathy. The irreversible formation of
AGEs affects proteins and lipids thus causing damage to the blood
vessels and kidneys.31 AGEs are found in almost all tissues exam-
ined from STZ-induced diabetic rats. Moreover, kidneys are more
susceptible to AGE formation than other tissues.32 Increased level
of AGE was found in the serum of STZ-diabetic rats whereas
treatment with MPGL lowered the elevated AGE levels. Thus MPGL
exhibited the potential to protect the kidney by decreasing the
formation of AGE in the circulation of the STZ-diabetic rats.etic nephropathy in streptozotocin-induced diabetic rats by Punica
Medicine (2016), http://dx.doi.org/10.1016/j.jtcme.2016.06.008
Fig. 4. Photomicrographs of kidney (Periodic Acid Schiff staining under light microscope at 400 magniﬁcation). A: Control rats; B: STZ-diabetic rats; C: 100 mg/kg MPGL treated
group; D: 200 mg/kg MPGL treated group; E: 400 mg/kg MPGL treated group. PP: PAS positivity, BM: Basement membrane thickening, G: glomeruli, þ: mild change, þþ: moderate
change.
S.N. Mestry et al. / Journal of Traditional and Complementary Medicine xxx (2016) 1e8 7Hyperglycemia leads to increased production of reactive oxygen
species (ROS) which are involved in the etiology of several diabetic
complications including diabetic nephropathy.28,33 The reactive
oxygen species deplete the antioxidant defenses of the cell thus
making it more susceptible to oxidative damage. It further targets
lipid, DNA and protein leading to their oxidation which further
leads to changes in cellular structure and function. GSH plays a
crucial role as a free radical scavenger in addition to the main-
tainance of plasma antioxidant status. Superoxide dismutase con-
verts superoxide to a less reactive ROS, hydrogen peroxide which is
further reduced to water by catalase. Thus, catalase assists SOD inPlease cite this article in press as: Mestry SN, et al., Attenuation of diab
granatum Linn. leaves extract, Journal of Traditional and Complementarythe complete neutralization of ROS.32 MDA, a late-stage lipid
oxidation byproduct, is an important indicator of free radical-
induced lipid peroxidation.28 Increased MDA levels are found in
mesangial cells, proximal tubule cells, plasma and renal cortex.32
Increased MDA levels were suppressed in STZ-diabetic rats
treated with MPGL. In addition to this, STZ-diabetic rats treated
with MPGL showed increased levels of GSH, SOD and catalase, thus
suggesting the antioxidant capacity of MPGL.
Histopathological examination of kidney sections of STZ-
diabetic rats showed severe vacuolar degeneration of tubules,
increased glomerular space, moderate intensity PAS positivity inetic nephropathy in streptozotocin-induced diabetic rats by Punica
Medicine (2016), http://dx.doi.org/10.1016/j.jtcme.2016.06.008
S.N. Mestry et al. / Journal of Traditional and Complementary Medicine xxx (2016) 1e88glomeruli and basement membrane thickening. Treatment with
MPGL signiﬁcantly reduced the aforementioned alterations, thus
demonstrating protective role in renal damage.
5. Conclusions
In the present investigation, administration of MPGL to STZ-
diabetic rats decreased blood glucose level, normalized the
cholesterol and triglycerides level, ameliorated the serum and urine
parameters along with normalization of kidney antioxidant status.
In summary, MPGL possesses antioxidant, antihyperglycemic,
antihyperlipidemic and anti-glycation activity and thus, exhibits a
protective action in STZ-induced diabetic nephropathy. Moreover,
further work is necessary to elucidate in detail the mechanism of
action of MPGL at the cellular and molecular levels.
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